Subcutaneously administered anti-IL-6 receptor antibody
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
1. An article of manufacture comprising a subcutaneous administration device, which contains and delivers to a patient a 162 mg fixed dose of tocilizumab.
2. The article of manufacture of claim 1 , wherein the subcutaneous administration device is selected from the group consisting of a syringe, an injection device, an infusion pump, an injector pen, a needleless device, an autoinjector, and a subcutaneous patch delivery system.
3. The article of manufacture of claim 2 , wherein the subcutaneous administration device is a syringe, including a pre-filled syringe.
4. The article of manufacture of claim 2 , wherein the subcutaneous administration device is an autoinjector.
5. An article of manufacture comprising a subcutaneous administration device, which contains and delivers to a patient a 162 mg fixed dose of an anti-IL-6R antibody, wherein the anti-IL-6R antibody comprises the light chain and heavy chain amino acid sequences of SEQ ID NOs:1 and 2, respectively.
6. The article of manufacture of claim 5 , wherein the subcutaneous administration device is selected from the group consisting of a syringe, an injection device, an infusion pump, an injector pen, a needleless device, an autoinjector, and a subcutaneous patch delivery system.
7. The article of manufacture of claim 6 , wherein the subcutaneous administration device is a syringe, including a pre-filled syringe.
8. The article of manufacture of claim 6 , wherein the subcutaneous administration device is an autoinjector.